During a press conference to announce a drug price deal for GLP-1s, President Donald Trump asked for more details about the ...

Darzalex Faspro’s approval for smoldering multiple myeloma could allow for earlier intervention and reduce the risk of ...

Following restricted vaccine approvals and changes to CDC immunization schedules, Merck, Pfizer, GSK and Sanofi are all ...

The FDA previously placed two clinical studies on hold, including the Phase III trial in which the liver toxicity occurred.

After a bidding war erupted between Pfizer and Novo Nordisk over the fledgling obesity drug maker, Metsera decided to side with its original suitor.

The Phase III results impressed Guggenheim Partners analysts both in terms of efficacy and safety. If approved, atacicept would become the first APRIL/BAFF inhibitor for IgAN to make it to the market.

The highest dose of Eli Lilly’s eloralintide led to 20.1% weight loss after 48 weeks in a Phase II trial, exceeding analyst ...

The agreement will also secure a $150 price for future weight loss pills from Novo Nordisk and Eli Lilly—at least initially.

The search continues for a new leader for the FDA’s Center for Drug Evaluation and Research after George Tidmarsh resigned on ...

Pressure from the FTC and Pfizer is building around Novo Nordisk’s bid to snatch obesity biotech Metsera: The antitrust ...

The company reported $200 million in net losses for the third quarter, but an aggressive and highly successful cost-cutting ...

The FDA awards a second round of Commissioner’s National Priority vouchers to six larger biopharma companies. And this time, ...